Highlights Hanall Biopharma Co., Ltd.

Equities

A009420

KR7009420001

End-of-day quote Korea S.E. Other stock markets 03:30:00 31/05/2024 am IST			5-day change	1st Jan Change
31,550 ^KRW	-14.50%		-11.87%	-28.78%

14/05	Hanall Biopharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03/05	HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Hanall Biopharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease	03/05	CI
Hanall Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03	CI
Hanall Biopharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab	11/22/11	CI
Hanall's Second FcRn Inhibitor HL161ANS to Be Added to the Development Program of Its Licensed Partner	04/22/04	CI
Tranche Update on Hanall Biopharma Co.,Ltd's Equity Buyback Plan announced on March 10, 2022.	15/22/15	CI
Hanall Biopharma Co.,Ltd's Equity Buyback announced on March 10, 2022, has expired with 519,451 shares, representing 1.01% for KRW 10,000.02 million.	10/22/10	CI
Hanall Biopharma Co.,Ltd announces an Equity Buyback for 543,479 shares.	10/22/10	CI
Hanall Biopharma Co.,Ltd authorizes a Buyback Plan.	10/22/10	CI
Hanall Biopharma Co.,Ltd Announces Consolidated Earnings Results for the Second Quarter and Six Months of 2021	29/21/29	CI
Hanall Biopharma Co.,Ltd Announces Earnings Results for the First Quarter Ended March 31, 2021	06/21/06	CI
HanAll Biopharma and Harbour Biomed Sign Collaboration and License Agreement for Development of Therapies in Greater China	12/17/12	CI
Biopharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate Vm202 for Non-Healing Diabetic Foot Ulcers	03/17/03	CI
Daewoong Pharmaceutical Co., Ltd. acquired 14.92% stake in HanAll Biopharma Co., Ltd. from Byung-Tae Kim, Sung-Soo Kim, Sung-Ji Kim, Dong-Shin Shin, and Hyun-Soo Kim for KRW 48 billion.	29/15/29	CI
Hanall Biopharma Co., Ltd. Announces Earnings Results for the First Half of Fiscal Year of 2014	26/14/26	CI
Kim Hong Cheol and two related parties acquired 5.3% stake in HanAll Biopharma Co., Ltd..	30/14/30	CI
Tranche Update on HanAll Biopharma Co., Ltd.'s Equity Buyback Plan announced on February 26, 2014.	29/14/29	CI
HanAll Biopharma Co., Ltd.’s Equity Buyback announced on May 8, 2013 has expired with 233,240 shares, representing 0.57% for KRW 995.69 million.	22/14/22	CI
HanAll Biopharma Co., Ltd. authorizes a Buyback Plan.	26/14/26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Hanall Biopharma Co., Ltd.

Equities

A009420

KR7009420001

Highlights

Filters